Waypoint Bio raises $20M to run three CAR-T trials in China
New York City-based startup Waypoint Bio has raised $20 million in Series A financing to test multiple cell therapies in China, the company told Endpoints…
Tacit Therapeutics Announces Series A Financing to Advance RNA Trans-Splicing Medicines for Inherited Diseases
Tacit Therapeutics, an RNA trans-splicing company developing programmable RNA repair medicines, today announced the closing of its Series A financing bringing the company’s total capital raised to $19 million.
Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced that the first patient has been dosed in its Phase 1/2 UNITE study evaluating MZ-1866, an investigational gene therapy for the treatment of Pitt Hopkins syndrome.
QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS
QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced interim data from its Proof-of-Concept Phase 1/2 ANQUR clinical trial of QRL-201 in people living with amyotrophic lateral sclerosis (ALS).
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionalizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced positive topline results from its RECONNECT Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression (PPD).
